TABLE 1.
Baseline characteristics of 18 trials included in the meta‐analysis
| Treatment Arm | No. HTN events | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study (year) | Study Design | Histology | Treatment Arm | No. patients | Control Arm | No. patients | Median Age | Median OS (month) | Median PFS (month) | All grade (HTN%) | High grade (HTN%) | CTACE | Ref |
| Vergote (2020) | Phase Ⅱ | EC | Len 24 mg QD | 133 | NA | NA | 62 (38‐80) | 10.6 (8.9‐14.9) | 5.4 (3.7‐6.3) | 65 (48.9%) | 41 (30.8) | 4 | 26 |
| Ueno (2020) | Phase Ⅱ | BTC | Len 24 mg QD | 26 | NA | NA | 64 (41‐78) | 7.35 (4.5‐11.27) | 3.19 (2.79‐7.23) | 22 (84.6) | 10 (38.5%) | 4 | 27 |
| Sato (2020) | Phase Ⅱ | Thymic carcinoma | Len 24 mg QD | 42 | NA | NA | 55.5(49‐65) | NA | 9.3 (7.7‐13.9) | 37 (88.1%) | 27 (64.3%) | 4 | 9 |
| Iwasa (2020) | Phase Ⅱ | CRC | Len 24 mg QD | 30 | NA | NA | 61.5 (42‐78) | 7.4 (6.4‐10.8) | 3.6 (2.6‐3.7) | 24 (80%) | 16 (53.3%) | 4 | 28 |
| Brose (2020) | Phase Ⅱ | RR‐DTC | Len 24 mg QD | 75 | NA | NA | NA | NA | NR (22.1‐NR) | NA | 19 (25.3%) | NA | 29 |
| Len 18 mg QD | 77 | NA | NA | NA | NA | 24.4(14.7‐NR) | NA | 15(19.5%) | NA | ||||
| Gao (2020) | Phase Ⅱ | Thymic carcinoma | Len 24 mg QD | 103 | Placebo | 48 | 60 | NA | 23.9 (12.9‐NE) | NA | 64 (62.1%) | NA | 30 |
| Tchekmedyian (2020) | Phase Ⅱ | ACC | Len 24 mg QD | 32 | NA | NA | 57 (38‐73) | NA | 17.5 (7.2‐NR) | NA | 9 (28.1%) | NA | 31 |
| Takahashi (2019) | Phase Ⅱ | TC | Len 24 mg QD | RR‐DTC:25 | NA | NA | 58(21‐74) | 31.8(31.8‐NR) | 25.8(18.4‐NR) | 24(96%) | 15(60%) | 4 | 32 |
| MTC:9 | NA | NA | 58 (41‐79) | 12.1 (3.8‐NR) | 9.2 (1.8‐NR) | 8 (88.9%) | 2 (22.2%) | 4 | |||||
| ATC:17 | NA | NA | 65 (36‐84) | 10.6 (3.8‐19.8) | 7.4 (1.7‐12.9) | 14 (82.4%) | 5 (29.4%) | 4 | |||||
| Hida (2019) | Phase Ⅱ | LAC | Len 24 mg QD | 25 | NA | NA | 63 (34‐78) | NA | 7.3 (3.6‐10.2) | 17 (68%) | 14 (56%) | NA | 33 |
| Kudo (2018) | Phase III | HCC | Len 12/8 mg QD | 478 | Sorafenib | 476 | 63 (22‐88) | 13.6 (12.1‐14.9) | 7.4 (6.9‐8.8) | 201 (42.1%) | 111 (23.2%) | 4 | 4 |
| Locati (2018) | Phase Ⅱ | ACC | Len 24 mg QD | 28 | NA | NA | 55 (22‐73) | 26.1 (11.1‐NR) | 9 (5.5‐14.2) | 21 (75%) | 5 (17.9%) | 4 | 34 |
| Ikeda (2017) | Phase Ⅱ | HCC | Len 12 mg QD | 46 | NA | NA | 66.5 (37‐80) | 18.7 (12.7‐25.1) | NA | 35 (76.1%) | 25 (54.3%) | 3 | 10 |
| Schlumberger (2016) | Phase Ⅱ | TC | Len 24 mg QD | 59 | NA | NA | 51.6 (22‐74) | 16.6 (16.4‐NE) | 9 (7‐NE) | 30 (50.8%) | 4 (0.7%) | NA | 35 |
| Schlumberger (2015) | Phase III | TC | Len 24 mg QD | 261 | Placebo | 131 | 64 | NE (22‐NE) | 18.3 (15.1‐NE) | 177 (67.8%) | 109 (41.8%) | 4 | 4 |
| Cabanillas (2015) | Phase Ⅱ | TC | Len 24 mg QD | 58 | NA | NA | 63 (34‐77) | NA | 12.6 (9.9‐16.1) | 44 (75.9%) | 6 (10.3%) | NA | 36 |
| Motzer (2015) | Phase Ⅱ | RCC | Len 24 mg QD | 52 | Lenvatinib + everolimus | 51 | 64 (41‐79) | 18.4 (13.3‐NE)) | 7.4 (5.6‐10.2) | 25 (48.1%) | 9 (17.3%) | 4 | 37 |
| Everolimus | 50 | 64 (41‐79) | |||||||||||
| O'Day (2013) | Phase Ⅱ | Melanoma | Len 24 mg QD | 93 | NA | NA | 64 | 9.5 (8.3‐12.9) | 3.7 (2.5‐4) | 55 (59.1%) | 32 (34.4%) | NA | 38 |
| Sherman (2011) | Phase Ⅱ | TC | Len 24 mg QD | 58 | NA | NA | 62 | NA | 12.6 (10.4‐14.1) | 37 (63.8%) | NA | NA | 39 |
EC, endometrial cancer; BTC, biliary tract cancer; CRC, colorectal cancer; RR‐DTC, radioiodine‐refractory differentiated thyroid cancer; ACC, adenoid cystic carcinoma; TC, thyroid cancer; LAC, lung adenocarcinoma; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; NA, not available; NE, not reached; Len, Lenvatinib.